While everyone is focused on pills versus injections, Novo Nordisk just made a move toward something completely different. On 7 July 2026, the Danish pharma giant announced a deal with Vivani Medical (NASDAQ: VANI) to evaluate NPM-139 - a miniature implant designed to deliver semaglutide continuously over months.
This is not a pill. It is not an injection. It’s a tiny device placed under the skin that slowly releases semaglutide over an extended period. If it works, it could change how GLP-1 drugs are administered entirely.
What Is NPM-139?
NPM-139 uses Vivani’s NanoPortal platform - a drug delivery technology that uses a miniature implant about the size of a grain of rice. The implant is inserted subcutaneously (under the skin) and designed to release semaglutide steadily over a period measured in months, not days or weeks.
The current weekly semaglutide injection (Wegovy) requires 52 injections per year. A once-daily oral tablet removes the needle but adds a daily routine with specific timing requirements. An implant that lasts three or six months would reduce the dosing burden to four or two interventions per year respectively.
According to the press release from Markets Insider and reporting by Fierce Biotech, the agreement is non-exclusive. Novo Nordisk will conduct an internal evaluation of semaglutide implants prepared by Vivani. It’s a partnership, not an acquisition - Novo is testing the technology before committing to clinical development.
What the Research Says
Vivani’s NanoPortal platform is not new. The company has been developing the implant technology for several years, with prior work focused on other compounds. The key engineering challenge is consistent drug release over an extended period - if the implant releases too much semaglutide early on (burst release) or too little later (trailing off), the therapeutic effect becomes unpredictable.
Drug delivery via implant has precedent. Hormone implants (testosterone, oestradiol) have been used for decades. Contraceptive implants like Nexplanon release etonogestrel over three years. The concept is proven. The challenge specific to semaglutide is the peptide’s molecular size and stability requirements.
Semaglutide is a large peptide molecule (4114 daltons) compared to the small molecules typically delivered via implant. Keeping it stable at body temperature over months without degradation is an engineering problem that has not been solved commercially.
Vivani’s stock (NASDAQ: VANI) surged on the announcement, reflecting market confidence that the technology has potential. But an evaluation agreement is a long way from a clinical programme, and a clinical programme is a long way from a product.
Why Delivery Method Matters
If you’ve been following the oral GLP-1 race, you know that delivery method is becoming the key battleground. The compound itself is converging - semaglutide, tirzepatide, and the next-generation triple agonists all work on similar pathways. What differs is how they get into your body:
- Injection (current Wegovy, Mounjaro) - weekly subcutaneous injection, effective but needle-dependent
- Oral tablet (Wegovy tablets, Foundayo/orforglipron) - daily pill, more convenient but less potent per dose and with specific timing requirements
- Implant (NPM-139, concept stage) - set-and-forget for months, but requires a minor procedure to insert and remove
- Microneedle patch (multiple early-stage companies) - painless application, but still very early in development
Each approach has trade-offs around convenience, efficacy, cost, and manufacturing complexity. The implant sits at the high-convenience, high-complexity end of that spectrum.
The Broader Strategy
Novo Nordisk’s deal with Vivani signals something bigger than one implant. It’s an acknowledgment that the company needs to diversify its delivery methods to stay competitive. The GLP-1 market is getting crowded:
- Eli Lilly has tirzepatide (Mounjaro/Zepbound) plus orforglipron (Foundayo) plus retatrutide in Phase 3
- AstraZeneca is pushing elecoglipron into Phase 3
- Pfizer’s Metsera pipeline includes multiple oral and injectable candidates
- Corxel’s CX11 showed promising Phase 2 oral data
Novo Nordisk’s core product is semaglutide. Finding new ways to deliver it - weekly injection, daily pill, implant - is how they defend market share against competitors with newer compounds. A semaglutide implant that works would be a moat.
What to Watch
This is very early. The agreement is for internal evaluation, not clinical trials. Realistic timeline for an NPM-139 clinical programme: 18-24 months before Phase 1 data, assuming the evaluation goes well. Market availability, if everything works, would be late 2028 at the earliest.
But the direction of travel matters. GLP-1 delivery is moving from “unpleasant necessity” (needles) toward “minimal friction” (pills, implants, patches). Each step removes a barrier to adoption and expands the addressable population.
For the Australian research community, keep an eye on whether implant delivery technologies make it through to TGA registration. Australia’s regulatory pathway for drug-device combination products (an implant is both a drug delivery system and a medical device) involves additional TGA requirements beyond standard pharmaceutical registration.
Sources
Source: Pharmaceutical Technology - Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant - published July 8, 2026 Source: Fierce Biotech - Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical - published July 7, 2026 Source: Markets Insider - Vivani Medical Enters into Agreement with Novo Nordisk - published July 7, 2026 Source: Yahoo Finance - Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant - published July 7, 2026
This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.